# US 2024/0189385 A1 · Keap1/nrf2 protein-like polymers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189385 A1
- Document ID: US20240189385A1
- Status: Published application
- Kind: A1
- Application number: 18/283,749
- Filed: 2022-04-04
- Published: 2024-06-13
- Earliest claimed: 2021-04-05
- Assignees: Northwestern University
- Applicants: Northwestern University
- Inventors: Nathan C. GIANNESCHI; Kendal Paige CARROW
- Web page: https://patentgrep.com/patent/US20240189385A1

## CPC

- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 47/58: obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/001: {by chemical synthesis}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C08L 89/00: Compositions of proteins; Compositions of derivatives thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)

## Abstract

In an aspect, the invention provides therapeutic agents comprising brush polymers that address challenges associated with conventional administration of free therapeutic peptides. In an embodiment, for example, the invention provides brush polymers incorporating one or more therapeutic peptides comprising a sequence having 75% or greater sequence identity of SEQ ID NO: 1 (LDEETGEFL) as side chain moieties. Therapeutic agents of the invention comprising brush polymers include high-density brush polymers including cross-linked brush polymers, brush block copolymers, and brush random copolymers. In an embodiment, brush polymers of the invention exhibit proteolysis-resistant characteristics and maintain their biological function during formulation and administration. The invention also includes methods of making and using therapeutic agents comprising brush polymers.

## Claims

### Claim 1

A peptide having from 11 to 16 amino acid residues comprising a sequence having 85% or greater sequence identity of SEQ ID NO: 1 (LDEETGEFL), wherein the peptide further comprises a charge modulating domain having from 2 to 7 amino acid residues.

### Claim 2 (depends on 1)

The peptide of claim 1, wherein the sequence having 85% or greater sequence identity of SEQ ID NO: 1 (LDEETGEFL) is SEQ ID NO: 1 (LDEETGEFL) or SEQ ID NO: 2 (LDPETGEFL).

### Claim at position 3

3-4. (canceled)

### Claim 5 (depends on 1)

The peptide of claim 1, wherein the charge modulating domain is a glycine-serine domain, a cationic residue domain, or a combination thereof.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The peptide of claim 1, wherein the peptide has a net positive charge.

### Claim 8 (depends on 1)

The peptide of claim 1, wherein the peptide has 11 to 15 amino acid residues.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The peptide of claim 1, wherein the peptide is
SEQ ID NO: 3
(LDEETGEFLRR)
SEQ ID NO: 4
(LDEETGEFLRRR)
SEQ ID NO: 5
(LDEETGEFLRRRR)
SEQ ID NO: 6
(LDEETGEFLRRRRR)
SEQ ID NO: 7
(RRLDEETGEFL)
SEQ ID NO: 8
(RRRLDEETGEFL)
SEQ ID NO: 9
(RRRRLDEETGEFL)
SEQ ID NO: 10
(RRRRRLDEETGEFL)
SEQ ID NO: 11
(RRLDEETGEFLRR)
SEQ ID NO: 12
(RRRLDEETGEFLRRR)
SEQ ID NO: 13
(RLDEETGEFLR)
SEQ ID NO: 14
(RLDEETGEFLRR)
SEQ ID NO: 15
(RRLDEETGEFLR)
SEQ ID NO: 16
(RLDEETGEFLRRR)
SEQ ID NO: 17
(RRRLDEETGEFLR)
SEQ ID NO: 18
(RLDEETGEFLRRRR)
SEQ ID NO: 19
(RRLDEETGEFLRRR)
SEQ ID NO: 20
(RRRLDEETGEFLRR)
SEQ ID NO: 21
(RRRRLDEETGEFLR)
SEQ ID NO: 22
(RLDEETGEFLRRRRR)
SEQ ID NO: 23
(RRLDEETGEFLRRRR)
SEQ ID NO: 24
(RRRRLDEETGEFLRR)
SEQ ID NO: 25
(RRRRRLDEETGEFLR)
SEQ ID NO: 26
(LDEETGEFLKK)
SEQ ID NO: 27
(LDEETGEFLKKK)
SEQ ID NO: 28
(LDEETGEFLKKKK)
SEQ ID NO: 29
(LDEETGEFLKKKKK)
SEQ ID NO: 30
(KKLDEETGEFL)
SEQ ID NO: 31
(KKKLDEETGEFL)
SEQ ID NO: 32
(KKKKLDEETGEFL)
SEQ ID NO: 33
(KKKKKLDEETGEFL)
SEQ ID NO: 34
(KKLDEETGEFLKK)
SEQ ID NO: 35
(KKKLDEETGEFLKKK)
SEQ ID NO: 36
(KLDEETGEFLK)
SEQ ID NO: 37
(KLDEETGEFLKK)
SEQ ID NO: 38
(KKLDEETGEFLK)
SEQ ID NO: 39
(KLDEETGEFLKKK)
SEQ ID NO: 40
(KKKLDEETGEFLK)
SEQ ID NO: 41
(KLDEETGEFLKKKK)
SEQ ID NO: 42
(KKLDEETGEFLKKK)
SEQ ID NO: 43
(KKKLDEETGEFLKK)
SEQ ID NO: 44
(KKKKLDEETGEFLK)
SEQ ID NO: 45
(KLDEETGEFLKKKKK)
SEQ ID NO: 46
(KKLDEETGEFLKKKK)
SEQ ID NO: 47
(KKKKLDEETGEFLKK)
SEQ ID NO: 48
(KKKKKLDEETGEFLK)
SEQ ID NO: 49
(LDEETGEFLKRKR)
SEQ ID NO: 50
(KRKRLDEETGEFL)
SEQ ID NO: 51
(RKRKLDEETGEFL)
SEQ ID NO: 52
(LDEETGEFLRKRK)
SEQ ID NO: 53
(KKLDEETGEFLRR)
SEQ ID NO: 54
(RRLDEETGEFLKK)
SEQ ID NO: 55
(KLDEETGEFLRRR)
SEQ ID NO: 56
(KKKLDEETGEFLR)
SEQ ID NO: 57
(RRRLDEETGEFLK)
SEQ ID NO: 58
(KRLDEETGEFLKR)
SEQ ID NO: 59
(RKLDEETGEFLRK)
SEQ ID NO: 60
(RKLDEETGEFLKR)
SEQ ID NO: 61
(KRLDEETGEFLRK)
SEQ ID NO: 62
(LDEETGEFLKKRR)
SEQ ID NO: 63
(LDEETGEFLRRKK)
SEQ ID NO: 64
(KKRRLDEETGEFL)
SEQ ID NO: 65
(RRKKLDEETGEFL)
SEQ ID NO: 66
(LDEETGEFLGSGSGRR)
SEQ ID NO: 67
(GSGSGRRLDEETGEFL)
SEQ ID NO: 68
(LDEETGEFLGSGSGKK)
SEQ ID NO: 69
(GSGSGKKLDEETGEFL)
SEQ ID NO: 70
(LDPETGEFLRR)
SEQ ID NO: 71
(LDPETGEFLRRR)
SEQ ID NO: 72
(LDPETGEFLRRRR)
SEQ ID NO: 73
(LDPETGEFLRRRRR)
SEQ ID NO: 74
(RRLDPETGEFL)
SEQ ID NO: 75
(RRRLDPETGEFL)
SEQ ID NO: 76
(RRRRLDPETGEFL)
SEQ ID NO: 77
(RRRRRLDPETGEFL)
SEQ ID NO: 78
(RRLDPETGEFLRR)
SEQ ID NO: 79
(RRRLDPETGEFLRRR)
SEQ ID NO: 80
(RLDPETGEFLR)
SEQ ID NO: 81
(RLDPETGEFLRR)
SEQ ID NO: 82
(RRLDPETGEFLR)
SEQ ID NO: 83
(RLDPETGEFLRRR)
SEQ ID NO: 84
(RRRLDPETGEFLR)
SEQ ID NO: 85
(RLDPETGEFLRRRR)
SEQ ID NO: 86
(RRLDPETGEFLRRR)
SEQ ID NO: 87
(RRRLDPETGEFLRR)
SEQ ID NO: 88
(RRRRLDPETGEFLR)
SEQ ID NO: 89
(RLDPETGEFLRRRRR)
SEQ ID NO: 90
(RRLDPETGEFLRRRR)
SEQ ID NO: 91
(RRRRLDPETGEFLRR)
SEQ ID NO: 92
(RRRRRLDPETGEFLR)
SEQ ID NO: 93
(LDPETGEFLKK)
SEQ ID NO: 94
(LDPETGEFLKKK)
SEQ ID NO: 95
(LDPETGEFLKKKK)
SEQ ID NO: 96
(LDPETGEFLKKKKK)
SEQ ID NO: 97
(KKLDPETGEFL)
SEQ ID NO: 98
(KKKLDPETGEFL)
SEQ ID NO: 99
(KKKKLDPETGEFL)
SEQ ID NO: 100
(KKKKKLDPETGEFL)
SEQ ID NO: 101
(KKLDPETGEFLKK)
SEQ ID NO: 102
(KKKLDPETGEFLKKK)
SEQ ID NO: 103
(KLDPETGEFLK)
SEQ ID NO: 104
(KLDPETGEFLKK)
SEQ ID NO: 105
(KKLDPETGEFLK)
SEQ ID NO: 106
(KLDPETGEFLKKK)
SEQ ID NO: 107
(KKKLDPETGEFLK)
SEQ ID NO: 108
(KLDPETGEFLKKKK)
SEQ ID NO: 109
(KKLDPETGEFLKKK)
SEQ ID NO: 110
(KKKLDPETGEFLKK)
SEQ ID NO: 111
(KKKKLDPETGEFLK)
SEQ ID NO: 112
(KLDPETGEFLKKKKK)
SEQ ID NO: 113
(KKLDPETGEFLKKKK)
SEQ ID NO: 114
(KKKKLDPETGEFLKK)
SEQ ID NO: 115
(KKKKKLDPETGEFLK)
SEQ ID NO: 116
(LDPETGEFLKRKR)
SEQ ID NO: 117
(KRKRLDPETGEFL)
SEQ ID NO: 118
(RKRKLDPETGEFL)
SEQ ID NO: 119
(LDPETGEFLRKRK)
SEQ ID NO: 120
(KKLDPETGEFLRR)
SEQ ID NO: 121
(RRLDPETGEFLKK)
SEQ ID NO: 122
(KLDPETGEFLRRR)
SEQ ID NO: 123
(KKKLDPETGEFLR)
SEQ ID NO: 124
(RRRLDPETGEFLK)
SEQ ID NO: 125
(KRLDPETGEFLKR)
SEQ ID NO: 126
(RKLDPETGEFLRK)
SEQ ID NO: 127
(RKLDPETGEFLKR)
SEQ ID NO: 128
(KRLDPETGEFLRK)
SEQ ID NO: 129
(LDPETGEFLKKRR)
SEQ ID NO: 130
(LDPETGEFLRRKK)
SEQ ID NO: 131
(KKRRLDPETGEFL)
SEQ ID NO: 132
(RRKKLDPETGEFL)
SEQ ID NO: 133
(LDPETGEFLGSGSGRR)
SEQ ID NO: 134
(GSGSGRRLDPETGEFL)
SEQ ID NO: 135
(LDPETGEFLGSGSGKK)
SEQ ID NO: 136
(GSGSGKKLDPETGEFL)
SEQ ID NO: 140
(YGRKKRRLDPETGEFL)
or
SEQ ID NO: 141
(LDPETGEFLYGRKKRR).

### Claim 11

A polymer comprising:
a first polymer segment comprising at least 2 first repeating units; wherein each of the first repeating units of the first polymer segment comprises a first polymer backbone group directly or indirectly covalently linked to a first polymer side chain group comprising a peptide;
wherein the peptide comprises a sequence having 75% or greater sequence identity of SEQ ID NO: 1 (LDEETGEFL).

### Claim 12 (depends on 11)

The polymer of claim 11, wherein the peptide comprises a sequence having 85% or greater sequence identity of SEQ ID NO: 1 (LDEETGEFL), SEQ ID NO: 2 (LDPETGEFL), SEQ ID NO: 137 (LDPTGEFL), or SEQ ID NO: 138 (LDPETGFL).

### Claim at position 12

13-17. (canceled)

### Claim 18 (depends on 11)

The polymer of claim 11, wherein the peptide further comprises a charge modulating domain having from 2 to 7 amino acid residues.

### Claim at position 14

19-25. (canceled)

### Claim 26 (depends on 11)

The polymer of claim 11, wherein the peptide is
SEQ ID NO: 3
(LDEETGEFLRR)
SEQ ID NO: 4
(LDEETGEFLRRR)
SEQ ID NO: 5
(LDEETGEFLRRRR)
SEQ ID NO: 6
(LDEETGEFLRRRRR)
SEQ ID NO: 7
(RRLDEETGEFL)
SEQ ID NO: 8
(RRRLDEETGEFL)
SEQ ID NO: 9
(RRRRLDEETGEFL)
SEQ ID NO: 10
(RRRRRLDEETGEFL)
SEQ ID NO: 11
(RRLDEETGEFLRR)
SEQ ID NO: 12
(RRRLDEETGEFLRRR)
SEQ ID NO: 13
(RLDEETGEFLR)
SEQ ID NO: 14
(RLDEETGEFLRR)
SEQ ID NO: 15
(RRLDEETGEFLR)
SEQ ID NO: 16
(RLDEETGEFLRRR)
SEQ ID NO: 17
(RRRLDEETGEFLR)
SEQ ID NO: 18
(RLDEETGEFLRRRR)
SEQ ID NO: 19
(RRLDEETGEFLRRR)
SEQ ID NO: 20
(RRRLDEETGEFLRR)
SEQ ID NO: 21
(RRRRLDEETGEFLR)
SEQ ID NO: 22
(RLDEETGEFLRRRRR)
SEQ ID NO: 23
(RRLDEETGEFLRRRR)
SEQ ID NO: 24
(RRRRLDEETGEFLRR)
SEQ ID NO: 25
(RRRRRLDEETGEFLR)
SEQ ID NO: 26
(LDEETGEFLKK)
SEQ ID NO: 27
(LDEETGEFLKKK)
SEQ ID NO: 28
(LDEETGEFLKKKK)
SEQ ID NO: 29
(LDEETGEFLKKKKK)
SEQ ID NO: 30
(KKLDEETGEFL)
SEQ ID NO: 31
(KKKLDEETGEFL)
SEQ ID NO: 32
(KKKKLDEETGEFL)
SEQ ID NO: 33
(KKKKKLDEETGEFL)
SEQ ID NO: 34
(KKLDEETGEFLKK)
SEQ ID NO: 35
(KKKLDEETGEFLKKK)
SEQ ID NO: 36
(KLDEETGEFLK)
SEQ ID NO: 37
(KLDEETGEFLKK)
SEQ ID NO: 38
(KKLDEETGEFLK)
SEQ ID NO: 39
(KLDEETGEFLKKK)
SEQ ID NO: 40
(KKKLDEETGEFLK)
SEQ ID NO: 41
(KLDEETGEFLKKKK)
SEQ ID NO: 42
(KKLDEETGEFLKKK)
SEQ ID NO: 43
(KKKLDEETGEFLKK)
SEQ ID NO: 44
(KKKKLDEETGEFLK)
SEQ ID NO: 45
(KLDEETGEFLKKKKK)
SEQ ID NO: 46
(KKLDEETGEFLKKKK)
SEQ ID NO: 47
(KKKKLDEETGEFLKK)
SEQ ID NO: 48
(KKKKKLDEETGEFLK)
SEQ ID NO: 49
(LDEETGEFLKRKR)
SEQ ID NO: 50
(KRKRLDEETGEFL)
SEQ ID NO: 51
(RKRKLDEETGEFL)
SEQ ID NO: 52
(LDEETGEFLRKRK)
SEQ ID NO: 53
(KKLDEETGEFLRR)
SEQ ID NO: 54
(RRLDEETGEFLKK)
SEQ ID NO: 55
(KLDEETGEFLRRR)
SEQ ID NO: 56
(KKKLDEETGEFLR)
SEQ ID NO: 57
(RRRLDEETGEFLK)
SEQ ID NO: 58
(KRLDEETGEFLKR)
SEQ ID NO: 59
(RKLDEETGEFLRK)
SEQ ID NO: 60
(RKLDEETGEFLKR)
SEQ ID NO: 61
(KRLDEETGEFLRK)
SEQ ID NO: 62
(LDEETGEFLKKRR)
SEQ ID NO: 63
(LDEETGEFLRRKK)
SEQ ID NO: 64
(KKRRLDEETGEFL)
SEQ ID NO: 65
(RRKKLDEETGEFL)
SEQ ID NO: 66
(LDEETGEFLGSGSGRR)
SEQ ID NO: 67
(GSGSGRRLDEETGEFL)
SEQ ID NO: 68
(LDEETGEFLGSGSGKK)
SEQ ID NO: 69
(GSGSGKKLDEETGEFL)
SEQ ID NO: 70
(LDPETGEFLRR)
SEQ ID NO: 71
(LDPETGEFLRRR)
SEQ ID NO: 72
(LDPETGEFLRRRR)
SEQ ID NO: 73
(LDPETGEFLRRRRR)
SEQ ID NO: 74
(RRLDPETGEFL)
SEQ ID NO: 75
(RRRLDPETGEFL)
SEQ ID NO: 76
(RRRRLDPETGEFL)
SEQ ID NO: 77
(RRRRRLDPETGEFL)
SEQ ID NO: 78
(RRLDPETGEFLRR)
SEQ ID NO: 79
(RRRLDPETGEFLRRR)
SEQ ID NO: 80
(RLDPETGEFLR)
SEQ ID NO: 81
(RLDPETGEFLRR)
SEQ ID NO: 82
(RRLDPETGEFLR)
SEQ ID NO: 83
(RLDPETGEFLRRR)
SEQ ID NO: 84
(RRRLDPETGEFLR)
SEQ ID NO: 85
(RLDPETGEFLRRRR)
SEQ ID NO: 86
(RRLDPETGEFLRRR)
SEQ ID NO: 87
(RRRLDPETGEFLRR)
SEQ ID NO: 88
(RRRRLDPETGEFLR)
SEQ ID NO: 89
(RLDPETGEFLRRRRR)
SEQ ID NO: 90
(RRLDPETGEFLRRRR)
SEQ ID NO: 91
(RRRRLDPETGEFLRR)
SEQ ID NO: 92
(RRRRRLDPETGEFLR)
SEQ ID NO: 93
(LDPETGEFLKK)
SEQ ID NO: 94
(LDPETGEFLKKK)
SEQ ID NO: 95
(LDPETGEFLKKKK)
SEQ ID NO: 96
(LDPETGEFLKKKKK)
SEQ ID NO: 97
(KKLDPETGEFL)
SEQ ID NO: 98
(KKKLDPETGEFL)
SEQ ID NO: 99
(KKKKLDPETGEFL)
SEQ ID NO: 100
(KKKKKLDPETGEFL)
SEQ ID NO: 101
(KKLDPETGEFLKK)
SEQ ID NO: 102
(KKKLDPETGEFLKKK)
SEQ ID NO: 103
(KLDPETGEFLK)
SEQ ID NO: 104
(KLDPETGEFLKK)
SEQ ID NO: 105
(KKLDPETGEFLK)
SEQ ID NO: 106
(KLDPETGEFLKKK)
SEQ ID NO: 107
(KKKLDPETGEFLK)
SEQ ID NO: 108
(KLDPETGEFLKKKK)
SEQ ID NO: 109
(KKLDPETGEFLKKK)
SEQ ID NO: 110
(KKKLDPETGEFLKK)
SEQ ID NO: 111
(KKKKLDPETGEFLK)
SEQ ID NO: 112
(KLDPETGEFLKKKKK)
SEQ ID NO: 113
(KKLDPETGEFLKKKK)
SEQ ID NO: 114
(KKKKLDPETGEFLKK)
SEQ ID NO: 115
(KKKKKLDPETGEFLK)
SEQ ID NO: 116
(LDPETGEFLKRKR)
SEQ ID NO: 117
(KRKRLDPETGEFL)
SEQ ID NO: 118
(RKRKLDPETGEFL)
SEQ ID NO: 119
(LDPETGEFLRKRK)
SEQ ID NO: 120
(KKLDPETGEFLRR)
SEQ ID NO: 121
(RRLDPETGEFLKK)
SEQ ID NO: 122
(KLDPETGEFLRRR)
SEQ ID NO: 123
(KKKLDPETGEFLR)
SEQ ID NO: 124
(RRRLDPETGEFLK)
SEQ ID NO: 125
(KRLDPETGEFLKR)
SEQ ID NO: 126
(RKLDPETGEFLRK)
SEQ ID NO: 127
(RKLDPETGEFLKR)
SEQ ID NO: 128
(KRLDPETGEFLRK)
SEQ ID NO: 129
(LDPETGEFLKKRR)
SEQ ID NO: 130
(LDPETGEFLRRKK)
SEQ ID NO: 131
(KKRRLDPETGEFL)
SEQ ID NO: 132
(RRKKLDPETGEFL)
SEQ ID NO: 133
(LDPETGEFLGSGSGRR)
SEQ ID NO: 134
(GSGSGRRLDPETGEFL)
SEQ ID NO: 135
(LDPETGEFLGSGSGKK)
SEQ ID NO: 136
(GSGSGKKLDPETGEFL)
SEQ ID NO: 140
(YGRKKRRLDPETGEFL)
or
SEQ ID NO: 141
(LDPETGEFLYGRKKRR).

### Claim at position 16

27-29. (canceled)

### Claim 30 (depends on 11)

The polymer of claim 11, wherein the polymer is a brush polymer, wherein the brush polymer is a high-density brush polymer characterized by a brush density greater than or equal to 50%.

### Claim at position 18

31-32. (canceled)

### Claim 33 (depends on 11)

The polymer of claim 11, wherein the first polymer segment comprises at least 5 first repeating units.

### Claim at position 20

34-38. (canceled)

### Claim 39 (depends on 11)

The polymer of claim 11, wherein at least a portion of the peptide side-chain is linked to the polymer backbone or consists of a degradable or triggerable linker.

### Claim 40

(canceled)

### Claim 41 (depends on 11)

The polymer of claim 11 characterized by the formula (FX1a), (FX1b), (FX1c), (FX1d); (FX1e); (FX1f); or (FX1g):
Q1-T-Q2 (FX1a);
Q1-T-[S]h-Q2 (FX1b);
Q1-[S]h-T-Q2 (FX1c);
Q1-[S]i-T-[S]h-Q2 (FX1d);
Q1-[S]i-T-[S]h-T-Q2 (FX1e);
Q1-T-[S]i-T-[S]h-Q2 (FX1f); or
Q1-T-[S]i-T-[S]h-T-Q2 (FX1g);
wherein each T is independently the first polymer segment comprising the first repeating units and each S is independently an additional polymer segment; Q1 is a first backbone terminating group; Q2 is a second backbone terminating group; and wherein h is zero or an integer selected over the range of 1 to 1000 and i is zero or an integer selected over the range of 1 to 1000; and
wherein each -T- is independently —[Y1]m—; wherein each Y1 is independently the first repeating unit of the first polymer segment; and each m is independently an integer selected from the range 0 to 1000, provided that at least one m is an integer selected from the range 1 to 1000.

### Claim 42

(canceled)

### Claim 43 (depends on 11)

The polymer of claim 11 characterized by the formula (FX2a), (FX2b), or (FX2c):
wherein
each Z1 is independently a first polymer backbone group and each Z2 is independently a second polymer backbone group;
each S is independently a repeating unit having a composition different from the first repeating unit;
Q1 is a first backbone terminating group and Q2 is a second backbone terminating group;
each L1 is independently a first linking group, each L2 is independently a second linking group;
each P1 is the peptide; wherein each P2 is a polymer side chain having a composition different from that of P1;
each m is independently an integer selected from the range of 2 to 1000;
each n is independently an integer selected from the range of 0 to 1000; and
each h is independently an integer selected from the range of 0 to 1000.

### Claim 44 (depends on 11)

The polymer of claim 11, wherein each of the first polymer backbone group and/or the second polymer backbone group is a substituted or unsubstituted polymerized norbornene, olefin, cyclic olefin, norbornene anhydride, cyclooctene, cyclopentadiene, styrene, acrylamide, or acrylate.

### Claim at position 27

45-56. (canceled)

### Claim 57 (depends on 1)

A pharmaceutical composition comprising the peptide of claim 1 and a pharmaceutically acceptable excipient.

### Claim 58 (depends on 1)

A method of treating or managing a condition comprising administering to a subject an effective amount of the peptide of claim 1.

### Claim 59

(canceled)

### Claim 60 (depends on 58)

The method of treating or managing a condition of claim 58, wherein the condition is associated with an inflammatory state, increased oxidative stress, autoimmune pathophysiology, chemo-preventative measures, neurodegeneration, or a combination thereof.

### Claim at position 32

61-66. (canceled)

### Claim 67 (depends on 58)

The method of treating or managing a condition of claim 58, wherein the condition is a cardiovascular disease or a neurodegenerative disease.

### Claim at position 34

68-70. (canceled)

### Claim 71 (depends on 58)

The method of treating or managing a condition of claim 58, wherein the method interrupts the protein-protein interaction between Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and Kelch-like ECH-Associating protein 1 (Keap1).

### Claim 72

A method of treating or managing a condition in a subject comprising:
administering to a subject an effective amount of a polymer comprising:
a first polymer segment comprising at least 2 first repeating units; wherein each of the first repeating units of the first polymer segment comprises a first polymer backbone group directly or indirectly covalently linked to a first polymer side chain group comprising a peptide;
wherein the peptide comprises a sequence having 75% or greater sequence identity of SEQ ID NO: 1 (LDEETGEFL).

### Claim 73 (depends on 72)

The method of treating or managing a condition of claim 72, wherein the condition is associated with an inflammatory state, increased oxidative stress, autoimmune pathophysiology, chemo-preventative measures, neurodegeneration, or a combination thereof.

### Claim 74 (depends on 72)

The method of treating or managing a condition of claim 72, wherein the condition is an autoimmune disease, a respiratory disease, a gastrointestinal disease, a cardiovascular disease, a neurodegenerative disease, or a combination thereof.

### Claim at position 39

75-79. (canceled)

### Claim 80 (depends on 72)

The method of treating or managing a condition of claim 72, wherein the condition is a cardiovascular disease or a neurodegenerative disease.

### Claim at position 41

81-83. (canceled)

### Claim 84 (depends on 72)

The method of claim 72, wherein the method interrupts the protein-protein interaction between Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and Kelch-like ECH-Associating protein 1 (Keap1).

### Claim 85 (depends on 72)

The method of claim 72, wherein the peptide comprises a sequence having 85% or greater sequence identity of SEQ ID NO: 1 (LDEETGEFL), SEQ ID NO: 2 (LDPETGEFL), SEQ ID NO: 137 (LDPTGEFL), or SEQ ID NO: 138 (LDPETGFL).

### Claim at position 44

86-90. (canceled)

### Claim 91 (depends on 72)

The method of claim 72, wherein the peptide further comprises a charge modulating domain having from 2 to 7 amino acid residues.

### Claim at position 46

92-95. (canceled)

### Claim 96 (depends on 72)

The method of claim 72, wherein the peptide has from 11 to 16 amino acid residues.

### Claim at position 48

97-98. (canceled)

### Claim 99 (depends on 72)

The method of claim 72, wherein the peptide is
SEQ ID NO: 3
(LDEETGEFLRR)
SEQ ID NO: 4
(LDEETGEFLRRR)
SEQ ID NO: 5
(LDEETGEFLRRRR)
SEQ ID NO: 6
(LDEETGEFLRRRRR)
SEQ ID NO: 7
(RRLDEETGEFL)
SEQ ID NO: 8
(RRRLDEETGEFL)
SEQ ID NO: 9
(RRRRLDEETGEFL)
SEQ ID NO: 10
(RRRRRLDEETGEFL)
SEQ ID NO: 11
(RRLDEETGEFLRR)
SEQ ID NO: 12
(RRRLDEETGEFLRRR)
SEQ ID NO: 13
(RLDEETGEFLR)
SEQ ID NO: 14
(RLDEETGEFLRR)
SEQ ID NO: 15
(RRLDEETGEFLR)
SEQ ID NO: 16
(RLDEETGEFLRRR)
SEQ ID NO: 17
(RRRLDEETGEFLR)
SEQ ID NO: 18
(RLDEETGEFLRRRR)
SEQ ID NO: 19
(RRLDEETGEFLRRR)
SEQ ID NO: 20
(RRRLDEETGEFLRR)
SEQ ID NO: 21
(RRRRLDEETGEFLR)
SEQ ID NO: 22
(RLDEETGEFLRRRRR)
SEQ ID NO: 23
(RRLDEETGEFLRRRR)
SEQ ID NO: 24
(RRRRLDEETGEFLRR)
SEQ ID NO: 25
(RRRRRLDEETGEFLR)
SEQ ID NO: 26
(LDEETGEFLKK)
SEQ ID NO: 27
(LDEETGEFLKKK)
SEQ ID NO: 28
(LDEETGEFLKKKK)
SEQ ID NO: 29
(LDEETGEFLKKKKK)
SEQ ID NO: 30
(KKLDEETGEFL)
SEQ ID NO: 31
(KKKLDEETGEFL)
SEQ ID NO: 32
(KKKKLDEETGEFL)
SEQ ID NO: 33
(KKKKKLDEETGEFL)
SEQ ID NO: 34
(KKLDEETGEFLKK)
SEQ ID NO: 35
(KKKLDEETGEFLKKK)
SEQ ID NO: 36
(KLDEETGEFLK)
SEQ ID NO: 37
(KLDEETGEFLKK)
SEQ ID NO: 38
(KKLDEETGEFLK)
SEQ ID NO: 39
(KLDEETGEFLKKK)
SEQ ID NO: 40
(KKKLDEETGEFLK)
SEQ ID NO: 41
(KLDEETGEFLKKKK)
SEQ ID NO: 42
(KKLDEETGEFLKKK)
SEQ ID NO: 43
(KKKLDEETGEFLKK)
SEQ ID NO: 44
(KKKKLDEETGEFLK)
SEQ ID NO: 45
(KLDEETGEFLKKKKK)
SEQ ID NO: 46
(KKLDEETGEFLKKKK)
SEQ ID NO: 47
(KKKKLDEETGEFLKK)
SEQ ID NO: 48
(KKKKKLDEETGEFLK)
SEQ ID NO: 49
(LDEETGEFLKRKR)
SEQ ID NO: 50
(KRKRLDEETGEFL)
SEQ ID NO: 51
(RKRKLDEETGEFL)
SEQ ID NO: 52
(LDEETGEFLRKRK)
SEQ ID NO: 53
(KKLDEETGEFLRR)
SEQ ID NO: 54
(RRLDEETGEFLKK)
SEQ ID NO: 55
(KLDEETGEFLRRR)
SEQ ID NO: 56
(KKKLDEETGEFLR)
SEQ ID NO: 57
(RRRLDEETGEFLK)
SEQ ID NO: 58
(KRLDEETGEFLKR)
SEQ ID NO: 59
(RKLDEETGEFLRK)
SEQ ID NO: 60
(RKLDEETGEFLKR)
SEQ ID NO: 61
(KRLDEETGEFLRK)
SEQ ID NO: 62
(LDEETGEFLKKRR)
SEQ ID NO: 63
(LDEETGEFLRRKK)
SEQ ID NO: 64
(KKRRLDEETGEFL)
SEQ ID NO: 65
(RRKKLDEETGEFL)
SEQ ID NO: 66
(LDEETGEFLGSGSGRR)
SEQ ID NO: 67
(GSGSGRRLDEETGEFL)
SEQ ID NO: 68
(LDEETGEFLGSGSGKK)
SEQ ID NO: 69
(GSGSGKKLDEETGEFL)
SEQ ID NO: 70
(LDPETGEFLRR)
SEQ ID NO: 71
(LDPETGEFLRRR)
SEQ ID NO: 72
(LDPETGEFLRRRR)
SEQ ID NO: 73
(LDPETGEFLRRRRR)
SEQ ID NO: 74
(RRLDPETGEFL)
SEQ ID NO: 75
(RRRLDPETGEFL)
SEQ ID NO: 76
(RRRRLDPETGEFL)
SEQ ID NO: 77
(RRRRRLDPETGEFL)
SEQ ID NO: 78
(RRLDPETGEFLRR)
SEQ ID NO: 79
(RRRLDPETGEFLRRR)
SEQ ID NO: 80
(RLDPETGEFLR)
SEQ ID NO: 81
(RLDPETGEFLRR)
SEQ ID NO: 82
(RRLDPETGEFLR)
SEQ ID NO: 83
(RLDPETGEFLRRR)
SEQ ID NO: 84
(RRRLDPETGEFLR)
SEQ ID NO: 85
(RLDPETGEFLRRRR)
SEQ ID NO: 86
(RRLDPETGEFLRRR)
SEQ ID NO: 87
(RRRLDPETGEFLRR)
SEQ ID NO: 88
(RRRRLDPETGEFLR)
SEQ ID NO: 89
(RLDPETGEFLRRRRR)
SEQ ID NO: 90
(RRLDPETGEFLRRRR)
SEQ ID NO: 91
(RRRRLDPETGEFLRR)
SEQ ID NO: 92
(RRRRRLDPETGEFLR)
SEQ ID NO: 93
(LDPETGEFLKK)
SEQ ID NO: 94
(LDPETGEFLKKK)
SEQ ID NO: 95
(LDPETGEFLKKKK)
SEQ ID NO: 96
(LDPETGEFLKKKKK)
SEQ ID NO: 97
(KKLDPETGEFL)
SEQ ID NO: 98
(KKKLDPETGEFL)
SEQ ID NO: 99
(KKKKLDPETGEFL)
SEQ ID NO: 100
(KKKKKLDPETGEFL)
SEQ ID NO: 101
(KKLDPETGEFLKK)
SEQ ID NO: 102
(KKKLDPETGEFLKKK)
SEQ ID NO: 103
(KLDPETGEFLK)
SEQ ID NO: 104
(KLDPETGEFLKK)
SEQ ID NO: 105
(KKLDPETGEFLK)
SEQ ID NO: 106
(KLDPETGEFLKKK)
SEQ ID NO: 107
(KKKLDPETGEFLK)
SEQ ID NO: 108
(KLDPETGEFLKKKK)
SEQ ID NO: 109
(KKLDPETGEFLKKK)
SEQ ID NO: 110
(KKKLDPETGEFLKK)
SEQ ID NO: 111
(KKKKLDPETGEFLK)
SEQ ID NO: 112
(KLDPETGEFLKKKKK)
SEQ ID NO: 113
(KKLDPETGEFLKKKK)
SEQ ID NO: 114
(KKKKLDPETGEFLKK)
SEQ ID NO: 115
(KKKKKLDPETGEFLK)
SEQ ID NO: 116
(LDPETGEFLKRKR)
SEQ ID NO: 117
(KRKRLDPETGEFL)
SEQ ID NO: 118
(RKRKLDPETGEFL)
SEQ ID NO: 119
(LDPETGEFLRKRK)
SEQ ID NO: 120
(KKLDPETGEFLRR)
SEQ ID NO: 121
(RRLDPETGEFLKK)
SEQ ID NO: 122
(KLDPETGEFLRRR)
SEQ ID NO: 123
(KKKLDPETGEFLR)
SEQ ID NO: 124
(RRRLDPETGEFLK)
SEQ ID NO: 125
(KRLDPETGEFLKR)
SEQ ID NO: 126
(RKLDPETGEFLRK)
SEQ ID NO: 127
(RKLDPETGEFLKR)
SEQ ID NO: 128
(KRLDPETGEFLRK)
SEQ ID NO: 129
(LDPETGEFLKKRR)
SEQ ID NO: 130
(LDPETGEFLRRKK)
SEQ ID NO: 131
(KKRRLDPETGEFL)
SEQ ID NO: 132
(RRKKLDPETGEFL)
SEQ ID NO: 133
(LDPETGEFLGSGSGRR)
SEQ ID NO: 134
(GSGSGRRLDPETGEFL)
SEQ ID NO: 135
(LDPETGEFLGSGSGKK)
SEQ ID NO: 136
(GSGSGKKLDPETGEFL)
SEQ ID NO: 140
(YGRKKRRLDPETGEFL)
or
SEQ ID NO: 141
(LDPETGEFLYGRKKRR).

### Claim at position 50

100-103. (canceled)
